Pneumonia is a significant cause of morbidity, accounting for 1.1 million admissions annually in the United States with an average length of stay of 5.2 days and annual healthcare costs of \$10.6 billion \[[@CIT0001], [@CIT0002]\]. Pneumonia is also the eighth leading cause of death with 53000 deaths in the United States and 3.1 million deaths globally \[[@CIT0003], [@CIT0004]\].

Scoring systems to predict 30-day mortality, such as the Pneumonia Severity Index (PSI), exist \[[@CIT0005]\], and although informative, the PSI is cumbersome requiring 20 data points, including age that may underrecognize severe illness in younger patients \[[@CIT0005]\]. Finally, the PSI was validated for community-acquired pneumonia (CAP); therefore, it may not be generalizable to patients who meet criteria for healthcare-associated pneumonia (HCAP) \[[@CIT0005]\].

Biomarkers are objective adjuncts to making the diagnosis of pneumonia. The biomarker procalcitonin (PCT) is a polypeptide precursor of calcitonin, which is produced ubiquitously by parenchymal cells in response to inflammatory cytokines with a rapid rise in the setting of bacterial infection \[[@CIT0006]\]. In contrast, viral infections result in downregulation of PCT synthesis, an effect mediated by interferon-γ \[[@CIT0007]\].

The ability of PCT to distinguish bacterial from viral etiologies of lower respiratory tract infections (LRTI) is established \[[@CIT0010]\]. In addition, studies have demonstrated that the use of PCT-guided algorithms can safely reduce antibiotic exposure in LRTI without an increase in adverse events \[[@CIT0010], [@CIT0011], [@CIT0014]\].

Although the role of PCT in the initial evaluation of LRTI is recognized, the contribution of PCT to clinical prognosis has yet to be defined. Several studies demonstrate an association between elevated PCT and mortality in septic patients \[[@CIT0017], [@CIT0018]\]. Although the addition of initial PCT to clinical indices improves prognostic performance of severity scores \[[@CIT0019], [@CIT0020]\], a large European study failed to validate these findings \[[@CIT0021]\]. Herein, we sought to characterize the prognostic role of serial PCT measurements in patients admitted with pneumonia for the composite primary endpoint of death, need for intensive care unit (ICU)-level care, and bacteremia.

METHODS {#s1}
=======

Study Design and Patients {#s2}
-------------------------

We conducted a prospective cohort study of patients admitted to a 999-bed tertiary care center in Boston, Massachusetts from March to September 2013. Eligible patients were admitted for at least 1 night with findings on chest imaging consistent with pneumonia. Exclusion criteria included age \<18, prior hospitalization within 14 days, concurrent ST-elevation myocardial infarction, cardiogenic shock, trauma or burns, requirement for emergent surgical intervention, and recent surgery. Procalcitonin was measured on days 1 through 4. The study was granted a waiver of informed consent by the Massachusetts General Hospital Institutional Review Board (Protocol no. 2012P001590).

Patient Screening and Selection {#s3}
-------------------------------

RENDER software \[[@CIT0022]\] identified chest radiology reports from the Emergency Department that included the term "pneumonia". After enrollment, chart review was performed by 2 independent physician reviewers, blinded to PCT values, to confirm a clinical diagnosis of pneumonia. Discordant adjudications were reviewed by committee (including an Infectious Diseases specialist) for final diagnosis.

Procalcitonin Measurement {#s4}
-------------------------

The VIDAS B-R-A-H-M-S PCT (bioMérieux, Inc., Durham, NC), an enzyme-linked fluorescent assay with a detection range of \<0.05 ng/mL to \>200 ng/mL, was used to measure plasma PCT. If insufficient sample volume was encountered, PCT was not recorded for that study day. If multiple samples were available, the earliest sample was used.

Data Collection {#s5}
---------------

Using REDCap \[[@CIT0023]\], a Health Insurance Portability and Accountability Act compliant data entry platform, clinical data were collected and independently verified including demographics, medical comorbidities, social history, initial vital signs, laboratory values, imaging findings, need for ICU-level care, and mortality. Pneumonia Severity Index was calculated for each study patient. The primary endpoint for the study was a composite outcome, defined as all-cause mortality, need for ICU-level care, or bacteremia.

Statistical Analysis {#s6}
--------------------

Overall population and subgroup analysis were performed based on final diagnosis of CAP or HCAP and of patients with PSI \>130. Discrete variables were expressed as counts (percentage) and continuous variables as medians and interquartile ranges. Frequency comparison was accomplished using the χ^2^ test. Mann-Whitney *U* test was applied for 2-group comparison for continuous data. We used univariate and multivariate logistic regression analysis to study the association between PCT levels (days 1 through 4) and primary endpoints. We adjusted for PSI in the multivariate analysis to correct for comorbidities that comprise the score. Area under the receiver-operating-characteristics (ROC) curve (AUC) was calculated to assess overall discrimination. To determine whether PCT improves the performance of PSI, ROC curves of the joint logistic regression of PCT and the PSI (including a model combining PCT values for all days) were compared with ROC curves limited to PSI alone. All analyses were performed on STATA 12.1 (StataCorp, College Station, TX). All statistical tests were 2-tailed, and *P* values less than .05 were considered to indicate statistical significance. Missing data points were not extrapolated.

RESULTS {#s7}
=======

Patient Population {#s8}
------------------

A total of 505 patients were enrolled. Twenty-five patients were excluded by criteria and sample errors. Four hundred eighty charts were reviewed by physicians blinded to PCT values, 20.4% of which ultimately required adjudication by committee to determine a final diagnosis. Of all patients, 191 (39.7%) were diagnosed with CAP, 126 (26.2%) with HCAP, 5 with viral pneumonia, and 158 (32.9%) with a condition other than pneumonia ([Figure 1](#F1){ref-type="fig"}). Only patients with a final diagnosis of bacterial CAP or HCAP (n = 317) were included in the analysis.

![Study flow diagram. CAP, community-acquired pneumonia; HCAP, healthcare-associated pneumonia; STEMI, ST elevation myocardial infarction.](ofw23801){#F1}

Of the 317 pneumonia patients, 25% met the composite primary endpoint. Sixteen patients died, 16 had bacteremia, and 65 required ICU-level care. Of those requiring ICU-level care, 36 required vasopressors, 27 required mechanical ventilation, and 22 required both of these critical care interventions. Baseline characteristics of patients who met the composite endpoint were similar to those who did not in regards to age, gender, race, smoking status, and underlying comorbidities ([Table 1](#T1){ref-type="table"}). An exception was nursing home residents, who comprised a higher proportion of those meeting the composite endpoint. Likewise, a greater proportion of patients meeting the combined endpoint had HCAP rather than CAP (63% versus 38%, *P* \< .01). Despite these differences at the time of admission, PSI was similar for the 2 groups.

###### 

Population Characteristics

  Variable                  Meeting Endpoint   Not Meeting Endpoint   
  ------------------------- ------------------ ---------------------- -------
  Age                       66 (26--95)        68 (22--100)           .41
  Male                      54 (68)            139 (59)               .16
  Race                                                                .64
   White                    52 (65)            161 (68)               
   African American         4 (5)              12 (5)                 
   Asian                    3 (4)              4 (2)                  
   Hispanic                 6 (8)              10 (4)                 
   Other                    16 (20)            50 (21)                
  Comorbidities                                                       
   Diabetes                 18 (23)            55 (23)                .90
   Heart Failure            17 (21)            47 (20)                .78
   Renal Failure            16 (20)            52 (22)                .71
    On hemodialysis         3 (4)              6 (3)                  
   Cirrhosis                2 (3)              12 (5)                 .27
   Malignancy               35 (44)            80 (34)                .11
  Underlying lung disease                                             
   Asthma                   15 (19)            34 (14)                .35
   COPD                     20 (25)            78 (33)                .19
   ILD                      6 (8)              9 (4)                  .18
   Lung cancer              10 (13)            20 (8)                 .28
  Living Situation                                                    \<.01
   Home                     53 (66)            199 (84)               
   Assisted Living          1 (1)              9 (4)                  
   Nursing Facility         21 (26)            13 (5)                 
   Other                    3 (4)              13 (5)                 
   Unknown                  2 (3)              3 (1)                  
  Active smoker             17 (21)            60 (25)                .46
  Type of Pneumonia                                                   \<.01
   CAP                      30 (38)            161 (68)               
   HCAP                     50 (63)            76 (32)                
  PSI                                                                 .36
   \<70                     2 (3)              9 (4)                  
   71--90                   5 (6)              20 (8)                 
   91--130                  27 (34)            99 (42)                
   \>130                    46 (58)            109 (46)               

Abbreviations: CAP, community-acquired pneumonia; COPD, chronic obstructive pulmonary disease; HCAP, healthcare-associated pneumonia; ILD, interstitial lung disease; PSI, Pneumonia Severity Index.

^a^Data are presented as mean (range) or n (%). *P* value for age was calcuated using a *t* test. *P* values for categorical variables were calcuated from χ^2^ analyses.

Procalcitonin Range for Outcomes {#s9}
--------------------------------

Procalcitonin measurements ranged from \<0.05 to 313.4 ng/mL. Patients with CAP who met the composite endpoint had significantly higher PCT values on days 1 through 3, whereas patients with HCAP who met the endpoint had higher values on days 1 and 2 ([Figure 2](#F2){ref-type="fig"}). Procalcitonin values for the components of the composite endpoint revealed that CAP patients requiring ICU-level care had significantly elevated PCT values on days 1 and 2, as opposed to days 3 and 4 for HCAP. Patients with bacteremia had higher PCT levels across all days for both CAP and HCAP. There was no significant difference in PCT values for patients who died versus those who survived ([Figure 2](#F2){ref-type="fig"}).

![Box plot representing the range, median, and first through third quartiles of procalcitonin values on hospital days 1 through 4 for patients with community- acquired pneumonia (A) and healthcare-associated pneumonia (B) who met the composite endpoint, developed bacteremia, required intensive care unit (ICU)-level care, or died. \**P* \< .05, \*\**P* \< .01, \*\*\**P* \< .001.](ofw23802){#F2}

Adverse Outcomes Associated With Elevated Procalcitonin {#s10}
-------------------------------------------------------

We next determined the ability of PCT to predict the composite endpoint as well as each individual component. A model combining PCT values on days 1 through 4 improved PCT performance when compared with PCT for any individual day (Supplemental Table 1). Using this combined PCT model to predict the composite primary endpoint, the AUC value was 0.66 for the total population (AUC 0.69 for CAP, 0.67 for HCAP). The AUC for the combined PCT model to predict the need for ICU-level care was 0.64 for the total population (AUC 0.65 for CAP, 0.67 for HCAP), and for bacteremia, the AUC was 0.84 for the total population (AUC 0.91 for CAP, 0.81 for HCAP) (Supplemental Table1, [Figure 3](#F3){ref-type="fig"}). Serial measurements of PCT did not predict mortality.

![Receiver operating characteristic curves for the performance of the Pneumonia Severity Index (PSI) alone versus a model of serial procalcitonin (PCT) values versus a combination of serial PCT values with the PSI to determine the composite study endpoint (A), need for intensive care unit (ICU)-level care (B), and bacteremia (C).](ofw23803){#F3}

Odds ratios (OR) for study endpoints were determined after multivariate logistic regression of PCT, corrected for the PSI, including each determinant (Supplemental Table 2). Elevated PCT values were predictive of bacteremia in the total population with OR ranging from 1.31 to 1.78 ([Figure 4A](#F4){ref-type="fig"}) and in patients with CAP with OR ranging from 1.34 to 2.62 (Supplemental Table 2). Procalcitonin also predicted need for ICU care, with peak effect seen on days 3 and 4 in the total population and patients with HCAP with OR of 1.21 to 1.28 and 1.24 to 1.40, respectively ([Figure 4A](#F4){ref-type="fig"}, Supplemental Table 2). For the composite endpoint, PCT predicted adverse events across all days in both the total population and in patients with CAP with OR ranging from 1.2 to 1.24 and 1.24 to 1.35, respectively (Supplemental Table 2).

![Multivariate regression analysis of the predictive value of procalcitonin (PCT) on hospital days 1 through 4 for death, need for intensive care unit-level care, bacteremia, and the composite endpoint in the total study population (n = 317) (A) and in patients with Pneumonia Severity Index (PSI) \>130 (n = 155) (B).](ofw23804){#F4}

Impact of Procalcitonin on the Performance of the Pneumonia Severity Index {#s11}
--------------------------------------------------------------------------

To determine whether PCT enhances PSI performance, we used a joint logistic regression model combining serial PCT (all days) and the PSI. The addition of serial PCT improved PSI's ability to predict the composite endpoint with an AUC of 0.66, compared with the PSI alone with an AUC of 0.61 ([Figure 3A](#F3){ref-type="fig"}). The combined model had an AUC of 0.64 compared with 0.58 for PSI alone in determining need for ICU-level care and 0.85 compared with 0.67 for bacteremia ([Figure 3B](#F3){ref-type="fig"} and [C](#F3){ref-type="fig"}).

Using Lower Respiratory Tract Infection Procalcitonin Cutoffs for Prognosis {#s12}
---------------------------------------------------------------------------

Several studies have validated PCT cutoff values of 0.1, 0.25, and 0.5 ng/mL to determine the probability of bacterial pneumonia \[[@CIT0010], [@CIT0014], [@CIT0024]\]. According to these studies, cutoff of 0.1 ng/mL is unlikely to represent bacterial infection, whereas levels greater than 0.25--0.5 ng/mL are more likely to represent bacterial pneumonia. In our study, we evaluated the performance of day 1 PCT at these cutoff values to predict study endpoints. For the total population at PCT values of 0.1, 0.25, and 0.5 ng/mL, sensitivity was 63%, 54%, and 46%, respectively, for the composite endpoint (Supplemental Table 3), all with negative predictive values (NPVs) \>80%. High NPV was also seen for the primary endpoint components of death, need for ICU-level care, and bacteremia at all PCT cutoffs. The specificity of PCT-based prognosis using these predetermined cutoff values was highest when evaluating the HCAP subpopulation, whereas sensitivity was highest in the CAP subpopulation.

Procalcitonin-Based Prediction of Adverse Outcomes in Patients With Severe Disease {#s13}
----------------------------------------------------------------------------------

One hundred fifty-five study patients (49%) had PSI \>130, placing them into the highest risk PSI category. In this group, we found that PCT continues to provide additional prognostic information, beyond the PSI. In the PSI \>130 group, PCT was a significant predictor of the composite endpoint, as well as bacteremia on all days 1 though 4, with OR ranging from 1.27 (95% confidence interval \[CI\], 1.05--1.52) to 1.31 (95% CI, 1.08--1.59) and 1.46 (95% CI, 1.08--1.98) to 1.70 (95% CI, 1.15--2.51), respectively. For ICU-level care, PCT was a predictor on hospital days 3 and 4 ([Figure 4B](#F4){ref-type="fig"}). In a multivariate regression model combining all PCT days, AUCs were 0.70, 0.69, and 0.81 for the composite endpoint, need for ICU-level care, and bacteremia, respectively (Supplemental Table 1). In addition, joint logistic regression analysis showed that PCT significantly improves PSI performance for the composite endpoint (AUC 0.63 to 0.72, *P* = .05), need for ICU-level care (AUC 0.58 to 0.7, *P* = .05), and bacteremia (AUC 0.59 to 0.83, *P* = .01).

DISCUSSION {#s14}
==========

Few studies have investigated the prognostic value of PCT \[[@CIT0017], [@CIT0025], [@CIT0026]\]. To our knowledge, these data represent the largest study in North America evaluating the prognostic potential of serial PCT levels in hospitalized patients with CAP and HCAP.

Despite an inability to predict all-cause mortality with PCT, we find that PCT accurately prognosticates the composite endpoint, which is driven by need for ICU-level care and bacteremia. Our data are consistent with others demonstrating that elevated PCT predicts bacteremia \[[@CIT0027]\]. In regards to bacteremia, applying the suggested LRTI cutoff values of PCT \>0.25 ng/mL and PCT \>0.5 ng/mL, our results show PCT sensitivities of 87.5% and 81.3% with NPV of 99% and 98.6%, respectively. Our study supports the use of serial PCT values over a single time point for predicting adverse outcomes ([Figure 3](#F3){ref-type="fig"}, Supplemental Table 1), although transition to clinical practice requires future research. We are aware of the Procalcitonin Monitoring Sepsis Study (MOSES, NCT01523717), which is a multicenter trial that highlights the utility of serial versus single PCT measurements when assessing prognosis in sepsis.

In addition to CAP, we investigated the role of PCT in patients with HCAP, a group with limited investigation in this field \[[@CIT0030], [@CIT0031]\]. It is interesting to note that there was no significant difference between PCT values for patients with CAP and HCAP. Elevated PCT levels were associated with adverse events, suggesting that PCT can be generalized to both pneumonia populations. Of the endpoints, we found that PCT is a better predictor of bacteremia and overall adverse events in patients with CAP versus HCAP. In contrast, PCT was a better predictor of ICU need in patients with HCAP, but later in the hospitalization (day 4), which may reflect host-specific immunity or bacterial etiology, both of which require further investigation.

Patients in the highest PSI risk category (PSI \>130, class V) represent a significant portion of patients admitted with pneumonia \[[@CIT0005]\] and the largest in our study (49% of the total population). Procalcitonin was able to further risk stratify patients in this highest PSI class ([Figure 4](#F4){ref-type="fig"}). Other studies have also found that PCT can be used for the evaluation of high-risk patients with pneumonia \[[@CIT0025], [@CIT0032]\], opening the possibility of more efficient healthcare use in this patient population.

The PCT cutoff values of 0.1, 0.25, and 0.5 ng/mL have been described in the determination for LRTI and PCT-guided antimicrobial therapy \[[@CIT0010], [@CIT0011], [@CIT0014]\]. We sought to determine whether these cutoffs were applicable for prognostication. Despite 46% of patients who met the primary endpoint having day 1 PCT values greater than 0.5 ng/mL, the accepted lower cutoffs for LRTI resulted in a striking NPV of \>80%. The positive predictive value ranged up to 50%, suggesting that an optimal cutoff for meeting an endpoint in our patient population is likely higher than 0.5 ng/mL. Furthermore, optimal cutoffs to predict adverse events may depend upon each specific patient population, which in this study trended toward patients with severe illness.

Despite several studies investigating serial PCT as a prognostic biomarker for mortality, data remain inconclusive \[[@CIT0033]\]. Both an early rise in PCT \[[@CIT0017]\] as well as persistent elevations in PCT have been shown to be independent risk factors for in-hospital mortality \[[@CIT0034]\]. In contrast, a large study in Denmark \[[@CIT0033]\] found that an initial PCT did not predict 90-day mortality. Likewise, our findings reveal that PCT does not independently predict mortality, nor does it improve the PSI in assessing this outcome, although our overall mortality is low at 5.7% and may be underpowered.

Limitations to our study include a single large tertiary care institution study with a heterogeneous patient population. We also note that the study period did not capture the influenza season, which may have provided additional insight regarding severe viral pneumonia and bacterial superinfection. Finally, given the observational study design, data were limited by availability of information in the medical record, and clinical providers did not have PCT results available to guide management. Prospective studies in which providers have PCT results available in real time will be required to define the number and frequency of PCT measurements to predict prognosis. Additional research focused on applying PCT-based prognostication to the effective use of healthcare resources is needed.

CONCLUSIONS {#s15}
===========

In conclusion, this study expands the ability of serial PCT values to improve the performance of clinical scores such as the PSI to predict need for ICU-level care and bacteremia. We also show that although still useful in patients with HCAP, the overall prognostic performance of PCT is best in the CAP population. Finally, this study highlights the utility of serial PCT measurements to predict adverse events in patients who fall into the highest PSI severity class.

Supplementary Data {#s16}
==================

Supplementary material is available at *Open Forum Infectious Diseases* online.
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